Altitude Lab, the Salt Lake City biotech accelerator founded by Recursion, says its portfolio companies have now raised more than $205 million in early-stage funding since the program launched in 2020, a milestone that signals growing momentum for Utah’s life sciences ecosystem.
The announcement comes at a time when biotech fundraising remains selective and many early-stage startups are facing a tougher capital environment. Against that backdrop, Altitude Lab’s latest numbers suggest that its model — backing platform-first biotech founders early and surrounding them with investors, operators, and lab resources — is starting to produce tangible results.
More importantly for Salt Lake City, the accelerator’s startups are no longer just early experiments. Several are moving into the clinic, signing strategic partnerships, and building technologies with commercial traction.
Source: Altitude Lab Portfolio Tops $205 Million in Funding as Salt Lake City’s Biotech Scene Gains Real Traction – TechBuzz News
